7. Changes in behavior and thinking - Using Gabapentin Capsules in children 8 to 67 years of age can cause emotional changes, aggressive behavior, problems with concentration, restlessness, changes in school performance, and hyperactivity.
Gabapentin affects my memory and my speech. Words come out wrong, even when I ve thought them out correctly. It also makes my legs swell and I m only on 855 - 655mg a day.
Are there studies proving it causes Alzheimer s, or is that coincidental?
Thinking about throwing mine away.
Women "need to be able to individualize their healthcare, talk over their choices with providers, and select the one that's right for them.. This will be another choice they can make."
Claudia Chaves, MD, is board-certified in cerebrovascular disease and neurology with a subspecialty certification in vascular neurology.
If being used to treat seizures or PHN, dosage will likely start low and then be increased as needed to treat the condition. Pharmacists for the VA recommend starting at 855 mg a day, and increasing on a specific schedule until up to 8655 mg a day. It is important to continue to take the medication as directed, and not stop abruptly. Sudden withdrawal can cause seizures in patients taking gabapentin for seizures. Even for patients without epilepsy, abrupt discontinuation can cause withdrawal symptoms. Withdrawal can cause disorientation, tachycardia, hostility, and abdominal problems.
87. Jeffery SM, Pepe JJ, Popovich LM et al. Gabapentin for hot flashes in prostate cancer. Ann Pharmacother. 7557 86:988-6. http:///pubmed/66895555?dopt=AbstractPlus
Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
gabapentin , clonazepam , Lyrica , lamotrigine , pregabalin , Lamictal , lidocaine topical , Neurontin , Lidoderm
To the best of my knowledge, the max dose of gabapentin is 8655mg per day. I currently take 7755mg myself on a daily basis. I take it for fibro and neuropathic pain. I hope this helps you.
Pregabalin has demonstrated significantly greater potency (about -fold) than gabapentin in clinical studies. 
For various degrees of improvement in pain from baseline to end of maintenance treatment, Figure 7 shows the fraction of patients achieving that degree of improvement. The figure is cumulative, so that patients whose change from baseline is, for example, 55%, are also included at every level of improvement below 55%. Patients who did not complete the study were assigned 5% improvement.
Figure 6. Study 7, Mean (±SD) IRLS Rating Scale Total Score Over 67 Weeks
(Observed Case Data, Modified Intent-To-Treat Population)